ABSTRACT
Pulmonary arterial hypertension (PAH) is a severe clinical condition that significantly affects patients' quality of life and survival. Since the emergence of prostanoids 45 years ago, different drugs acting on vasoconstriction/vasodilation mechanisms have been developed for the treatment of PAH. Current evidence shows that better results occur when combined therapy is initiated up-front with periodic and systematized evaluations for escalation and switching. Among these strategies, riociguat has a relevant role, supported by the results of several clinical studies. This document issues recommendations by a panel of experts who analysed and discussed the indications and limitations for riociguat in PAH in different institutions of the Mexican health system.
Subject(s)
Pulmonary Arterial Hypertension , Humans , Pulmonary Arterial Hypertension/drug therapy , Pyrazoles/pharmacology , Pyrazoles/therapeutic use , Pyrimidines/pharmacology , Pyrimidines/therapeutic use , Quality of LifeABSTRACT
Resumen: El síndrome de la vena cava superior es un conjunto de signos y síntomas desencadenados por la obstrucción de la vena cava superior. Los tumores intratorácicos malignos son la principal causa. Sin embargo, en las últimas décadas se han descrito causas benignas, como la trombosis asociada con la colocación de accesos venosos.
Abstract: Superior vena cava syndrome is a set of signs and symptoms due to superior vena cava obstruction. Intratoracic malignant tumors are the main cause. However, in last decades benign causes such as thrombosis related to venous access colocation have been described.
